Mandate

Vinge advises Fouriertransform in connection investment in El-Forest

July 06, 2010

Vinge has advised Fouriertransform in connection with its investment in El-Forest. El-Forest has developed the world’s first forestry machine that uses energy efficient electric-hybrid technology. The technology gives rise to several environmental improvement measures. The investment is taking place through a directed new share issue pursuant to which Fouriertransform will become the largest individual shareholder. El-Forest’s forestry machine has a unique and patented track following and hybrid operation system which reduces fuel consumption, carbon dioxide emissions and reduces damage to forests due to the light weight of the machine.

Fouriertransform is a state-owned venture capital company which commercially supports innovative companies and entrepreneurs who can contribute to stimulating the Swedish vehicle industry.

Fouriertransform was represented in the negotiations by partner Bo Adrianzon and associate Johan Steen. Associates Sofia Berg and Adam Weissbach (IP) assisted in the due diligence phase.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025